While not seen in our normal sample, which was collected at 1-year post-CAR-T, this TET2 mutation was found in the clinical next-generation sequencing panel performed on PBMCs collected three months after the new lymphadenopathy presented, raising the possibility of clonal evolution or clonal hematopoiesis of indeterminate potential. This evidence concerns the gene TET2 and Lymphadenopathy.